Skip to content

Author

Mark J. Caulfield

We have 2 of 33 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Metabolomics in Early-Phase Clinical Trials from 2010 to 2025

An international assessment of metabolomics integration in registered early-phase clinical trials provides an international assessment of metabolomics integration in registered early-phase clinical trials and concludes that metabolomics remains underutilised in early-phase clinical trials.

Jack T. Thompson, Maia Megase, M. Boffito et al. · 0 citations
Open access Sep 2026

Proteomics identify disease-associated variants in patients with rare diseases undiagnosed after genome sequencing.

It is demonstrated that serum proteomics can support rare disease diagnosis and identify disease-causing genes in patients undiagnosed after GS, although successful implementation will likely depend on tissue specificity of protein expression, detectability in blood, proteomic platform coverage, and sensitivity.

J. Carrasco-Zanini, J. Andrade, M. Pietzner et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.